International Medical Journal, Vol. 22., Iss. 4, 2016, P. 63−66.
THE FEATURES OF REPRODUCTIVE FUNCTION IN WOMEN WITH BREAST CANCER
National Center of Oncology, Baku, Azerbaijan Republic
Breast cancer (BC) is the most common tumor in women; in 12 % of cases it is revealed at the age of 20−34, that is at the height of reproductive function. Given that the treatment for breast cancer often includes chemotherapy and hormone therapy, which negatively impact the reproductive function, its evaluation is important. It is more likely for those women who were did not have pregnancy before the diagnosis. The test of ovarian reserve, which includes determining the level of follicle−stimulating, luteinizing anti−Mullerian hormones, estradiol, inhibin B, and antral follicle count on days 2−5 of the menstrual cycle, is one of methods to assess fertility. But performing these tests after chemotherapy for breast cancer shows that they do not reliably predict the response to ovarian stimulation. Numerous studies on the use of tamoxifen as hormone therapy have indicated possible teratogenic effects of this drug. Although the data are inconsistent due to the fact that a single strategy of hormonal therapy, taking into account the dose, duration, combination preparations. The search for chemotherapy regimens and hormonal therapy for treatment of pregnant women who are diagnosed breast cancer goes on.
Key words: breast cancer, reproductive function, pregnancy, chemotherapy, hormone therapy.